(Press-News.org) Cambridge, MA, February 17, 2025 — Insilico Medicine (“Insilico”, 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and Memorial Sloan Kettering Cancer Center (MSK) have entered into a collaborative research agreement aimed at discovering new therapeutic targets for gastroesophageal malignancies. The initiative builds on MSK’s global leadership in this field under the direction of Yelena Y. Janjigian, MD, Carroll and Milton Petrie Chair; Chief, GI Oncology; and Founding Director of the MSK GEC Therapeutics Accelerator, whose group has delivered multiple practice-changing advances in gastric and gastroesophageal junction cancers. Patrick Evans, BS, MBA, Senior Project Manager in the Janjigian Lab, will serve as the MSK project lead, supporting integration of scientific, operational, and translational efforts across teams.
Insilico Medicine's multidisciplinary team will utilize its PandaOmics platform and other proprietary tools to accelerate the discovery of new disease mechanisms and target hypotheses. PandaOmics is an AI-driven biological data analysis platform developed and designed to accelerate drug target discovery by integrating advanced, multi-dimensional artificial intelligence (AI) and bioinformatics models with multimodal omics and biomedical text data for therapeutic target and biomarker identification. The platform utilizes over 20 proprietary AI and bioinformatic models to systematically prioritize druggable biological targets with high translational potential.
A central strength of the project is the integration of MSK’s extensive multi-omic clinical datasets into PandaOmics. MSK contributes high quality patient genomic, proteomic, and transcriptomic data and deeply annotated clinical cohorts, providing a rich foundation for systematic analysis and identification of disease drivers across diverse GEC subtypes. By combining MSK’s world-class clinical and translational expertise with Insilico’s AI powered platforms, the joint project teams aim to uncover actionable targets and biological pathways that may lead to future personalized therapeutic options and improved outcomes for patients with gastroesophageal cancers.
The collaboration is currently centered on data gathering, quality control, and integration. Subsequent phases anticipate involving AI driven hypothesis generation, target ranking, and detailed biological investigation. The project also supports the evaluation and advancement of identified targets across a range of therapeutic modalities, including biologics and small molecules.
"This collaboration with MSKbrings together leading clinical oncology expertise with our generative AI platforms," said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. "Gastroesophageal cancers remain among the most challenging solid tumors. By integrating MSK’s exceptional clinical data resources with our target discovery technologies, we aim to identify meaningful biological insights and accelerate the development of new therapeutic options for patients worldwide."
Reflecting on the collaboration, Dr. Janjigian noted: “GEC patients need new breakthroughs, and those breakthroughs must come from a deeper understanding of each patient’s unique disease biology. By combining patient-level clinical and molecular data with transformative AI tools, we can accelerate the discovery of clinically meaningful targets and move more personalized therapies toward patients who need them most, in real time and faster.”
Harnessing state-of-the-art AI and automation technologies, Insilico has significantly improved the efficiency of preclinical drug development, setting a benchmark for AI-driven drug R&D. While traditional early-stage drug discovery typically requires an average of 4.5 years, Insilico has nominated 20 preclinical candidates from 2021 to 2024, with an average timeline—from project initiation to preclinical candidate (PCC) nomination—of just 12 to 18 months per program, with only 60 to 200 molecules synthesized and tested in each program.
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 3696.HK.
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com
END
Insilico Medicine initiates AI driven collaboration with leading global cancer center to identify novel targets for gastroesophageal cancers
2026-02-17
ELSE PRESS RELEASES FROM THIS DATE:
Immunotherapy plus chemotherapy before surgery shows promise for pancreatic cancer
2026-02-17
A new UCLA investigator-initiated study sponsored by the UCLA Health Jonsson Comprehensive Cancer Center has found that adding immunotherapy to standard chemotherapy before surgery is safe and shows promise for some patients with borderline-resectable pancreatic cancer, a disease that has historically been difficult to treat. The findings, published in Nature Communications, show that while the combination did not produce a clear survival advantage for most patients, a notable subset experienced unusually ...
A “smart fluid” you can reconfigure with temperature
2026-02-17
Imagine a “smart fluid” whose internal structure can be rearranged just by changing temperature.
In a new study in Matter, researchers report a way to overcome a long-standing limitation in a class of “smart fluids” called nematic liquid crystal microcolloids, allowing for reconfigurable self-assembly of micrometer-sized particles dispersed in a nematic liquid crystal host.
The persistent challenge has been that conventional microparticles can induce strong distortions and topological defects in the liquid crystal, which in turn can drive irreversible sticking and clumping, making ...
New research suggests myopia is driven by how we use our eyes indoors
2026-02-17
New York, NY — For years, rising rates of myopia — or nearsightedness — have been widely attributed to increased screen time, especially among children and young adults. But new research from scientists at the SUNY College of Optometry suggests the story may be more complicated — and more human. In a new study to be published in Cell Reports, researchers propose that myopia may be driven less by screens themselves and more by a common indoor visual habit: prolonged close-up focus in low-light environments, which limits how much light reaches ...
Scientists develop first-of-its-kind antibody to block Epstein Barr virus
2026-02-17
SEATTLE – February 17, 2026 – Fred Hutch Cancer Center scientists reached a crucial milestone in blocking Epstein Barr virus (EBV), a pathogen estimated to infect 95% of the global population that is linked to multiple types of cancer, neurodegenerative diseases and other chronic health conditions.
Using mice with human antibody genes, the research team developed new genetically human monoclonal antibodies that prevent two key antigens on the surface of the virus from binding to and entering human immune cells. Published in Cell Reports Medicine, the ...
With the right prompts, AI chatbots analyze big data accurately
2026-02-17
In an early test of how AI can be used to decipher large amounts of health data, researchers at UC San Francisco and Wayne State University found that generative AI tools could perform orders of magnitude faster — and in some cases better than computer science teams that had spent months poring over the data.
Teams of scientists and scientists paired with AI were given the same task: predict preterm birth based on data from more than 1,000 pregnant women.
Even a junior research duo composed of a master’s student at UCSF, Reuben Sarwal, and a high school ...
Leisure-time physical activity and cancer mortality among cancer survivors
2026-02-17
About The Study: In this analysis of 6 pooled cohorts, higher levels of moderate to vigorous physical activity (MVPA) after a cancer diagnosis were associated with lower risk of cancer mortality among people previously diagnosed with 1 of 7 cancers not commonly studied for their association with MVPA. These findings suggest that it is important for health care professionals to promote physical activity for longevity and overall health among people living with and beyond cancer.
Corresponding Author: To contact the corresponding author, Erika Rees-Punia, PhD, email erika.rees-punia@cancer.org.
To ...
Chronic kidney disease severity and risk of cognitive impairment
2026-02-17
About The Study: This cohort study of patients with chronic kidney disease (CKD) suggests that a more advanced CKD stage was associated with increased incidence of cognitive impairment. These findings underscore CKD severity as a risk factor for cognitive decline across the CKD spectrum.
Corresponding Author: To contact the corresponding author, Tanika N. Kelly, PhD, MPH, email tkelly5@uic.edu,
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2025.59834)
Editor’s ...
Research highlights from the first Multidisciplinary Radiopharmaceutical Therapy Symposium
2026-02-17
PALM DESERT, Ca., February 17, 2026 — New research highlighting the growing potential of radiopharmaceutical therapies (RPT) to improve outcomes for people with cancer will be presented at the inaugural Multidisciplinary Radiopharmaceutical Therapy Symposium, taking place in Palm Desert, California, and online starting today. Studies at the meeting, sponsored by the American Society for Radiation Oncology (ASTRO), span established uses of RPT and early signals for new indications, while also addressing what clinics need in place to safely offer these treatments as they move into ...
New guidelines from NCCN detail fundamental differences in cancer in children compared to adults
2026-02-17
PLYMOUTH MEETING, PA [February 17, 2026] — The National Comprehensive Cancer Network® (NCCN®) today published new NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Pediatric Soft Tissue Sarcomas. This is the 7th NCCN Guidelines® for a pediatric cancer, expanding the overall library to cover 91 topics in cancer care. The guidelines present the latest evidence-based, expert consensus-driven recommendations for nearly every type of cancer plus prevention, screening, survivorship, and supportive care. NCCN Guidelines are updated at least once a year and help cancer care providers worldwide ...
Four NYU faculty win Sloan Foundation research fellowships
2026-02-17
Four New York University faculty have been awarded fellowships from the Alfred P. Sloan Foundation: Danique Jeurissen, an assistant professor of neural science, and Marvin Parasram, an assistant professor of chemistry, as well as Florian Schäfer and Joseph Tassarotti, assistant professors in NYU’s Courant Institute School of Mathematics, Computing, and Data Science.
“The Sloan Research Fellows are among the most promising early-career researchers in the US and Canada, already driving meaningful progress in their respective disciplines,” says Stacie Bloom, president and chief executive officer of the Alfred P. Sloan Foundation. “We look forward to seeing ...